Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated)

American Journal of Respiratory and Critical Care Medicine

Volumn 176, Issue 5, 2007, Pages 483-490

  Levi, Marcel ^a   Levy, Mitchell ^b   Williams, Mark D ^c   Douglas, Ivor ^d   Artigas, Antonio ^e   Antonelli, Massimo ^f   Wyncoll, Duncan ^g   Janes, Jonathan ^c   Booth, Frank V ^c   Wang, Dazhe ^c   Sundin, David P ^c   Macias, William L ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b BROWN UNIVERSITY   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f CATHOLIC UNIVERSITY   (Italy)

^g GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Clinical trial; Critical care; Recombinant human activated protein C; XPRESS

Indexed keywords

DROTRECOGIN; ENOXAPARIN; HEPARIN; PLACEBO;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SEPSIS; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

EID: 34548456526     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200612-1803OC     Document Type: Article

References (35)

1. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al.; Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-873.
2. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, Sicignano A, Palazzo M, Moreno R, Boulme R, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002;28:108-121.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-1310.
4. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-1554.
5. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D; Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006;34:344-353.
6. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
7. Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson B, Brandt JT, Sundin DP, Levi M. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004;2:1924-1933.
8. Cook DJ, Crowther MA, Meade MO, Douketis J, for the VTE in the ICU Workshop Participants. Prevalence, incidence, and risk factors for venous thromboembolism in medical-surgical intensive care unit patients. J Crit Care 2005;20:309-313.
9. Perez J, Dellinger RP, and International Sepsis Forum. Other supportive therapies in sepsis. Intensive Care Med 2001;27(Suppl 1):S116-S127.
10. Patel R, Cook DJ, Meade MO, Griffith LE, Mehta G, Rocker GM, Marshall JC, Hodder R, Martin CM, Heyland DK, et al.; Burden of Illness in venous ThromboEmbolism in Critical care (BITEC) Study Investigators; Canadian Critical Care Trials Group. Burden of illness in venous thromboembolism in critical care: a multicenter observational study. J Crit Care 2005;20:341-347.
11. Corrigan JJ Jr. Heparin therapy in bacterial septicemia. J Pediatr 1977;91:695-700.
12. Davidson BL, Geerts WH, Lensing AW. Low-dose heparin for severe sepsis. N Engl J Med 2002;347:1036-1037.
13. Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood 1982;60:284-287.
14. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586-592.
15. Boldt J, Papsdorf M, Piper SN, Rothe A, Hempelmann G. Continuous heparinization and circulating adhesion molecules in the critically ill. Shock 1999;11:13-18.
16. Derhaschnig U, Pernerstorfer T, Knechtelsdorfer M, Hollenstein U, Panzer S, Jilma B. Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemia. Crit Care Med 2003;31:1108-1112.
17. Meyer J, Cox CS, Herndon DN, Nakazawa H, Lentz CW, Traber LD, Traber DL. Heparin in experimental hyperdynamic sepsis. Crit Care Med 1993;21:84-89.
18. Pernerstorfer T, Hollenstein U, Hansen J, Knechtelsdorfer M, Stohlawetz P, Graninger W, Eichler HG, Speiser W, Jilma B. Heparin blunts endotoxin-induced coagulation activation. Circulation 1999;100:2485-2490.
19. Tanaka T, Tsujinaka T, Kambayashi J, Higashiyama M, Yokota M, Sakon M, Mori T. The effect of heparin on multiple organ failure and disseminated intravascular coagulation in a sepsis model. Thromb Res 1990;60:321-330.
20. Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, et al.; Recombinant Human Activated Protein C Worldwide Evaluation in Sepsis (PROWESS) Study Group. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 2003;29:894-903.
21. Anti-Infective Advisory Committee. FDA briefing document: drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)] Xigris. BLA #125029/0. Rockville, MD: Food and Drug Administration, September 12, 2001. Available from: http://www.fda.gov/ohrms/dockets/ac/01/briefing/ 3797b1_02_FDAbriefing.pdf (accessed June 13, 2006).
22. Aznar J, Espana F, Estelles A, Royo M. Heparin stimulation of the inhibition of activated protein C and other enzymes by human protein C inhibitor: influence of the molecular weight of heparin and ionic strength. Thromb Haemost 1996;76:983-988.
23. Friedrich U, Blom AM, Dahlback B, Villoutreix BO. Structural and energetic characteristics of the heparin-binding site in antithrombotic protein C. J Biol Chem 2001;276:24122-24128.
24. Pratt CW, Church FC. General features of the heparin-binding serpins antithrombin, heparin cofactor II and protein C inhibitor. Blood Coagul Fibrinolysis 1993;4:479-490.
25. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-829.
26. Cook D, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, Geerts W, Guyatt G. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med 2005;33:1565-1571.
27. Fraisse F, Holzapfel L, Couland JM, Simonneau G, Bedock B, Feissel M, Herbecq P, Pordes R, Poussel JF, Roux L. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 2000;161:1109-1114.
28. Ibrahim EH, Iregui M, Prentice D, Sherman G, Kollef MH, Shannon W. Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis. Crit Care Med 2002;30:771-774.
29. Marik PE, Andrews L, Maini B. The incidence of deep venous thrombosis in ICU patients. Chest 1997;111:661-664.
30. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793-800.
31. Bahit MC, Topol EJ, Califf RM, Armstrong PW, Criger DA, Hasselblad V, Betriu A, Hirsh J, Ardissino D, Granger CB. Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes. J Am Coll Cardiol 2001;37:1001-1007.
32. Bijsterveld NR, Moons AH, Meijers JC, Tijssen JG, Buller HR, Levi M, Peters RJ. Rebound thrombin generation after heparin therapy in unstable angina: a randomized comparison between unfractionated and low-molecular-weight heparin. J Am Coll Cardiol 2002;39:811-817.
33. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141-145.
34. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francxois B, Guy JS, Brückmann M, Rea-Neto A, et al.; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332-1341.
35. Hirsch DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA 1995;274:335-337.